Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

It's a big day for Mesoblast Ltd (ASX: MSB) shares today.

Not because shares in the clinical-stage biotechnology company are gaining again. In fact, they're headed the other direction on Friday, down 8.1% in early afternoon trade at $1.635 apiece.

There's no need to break out your tiny violin for longer-term stockholders, though. As you can see on the chart below, Mesoblast shares remain up an eye-watering 427% in 2024.

Rather, today is a big day for the company because Mesoblast hosted its annual general meeting (AGM) this morning.

Here's what the company's top management had to say.

Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

Mesoblast shares in focus amid AGM

"This year has seen our company make significant advances as a leading developer of innovative allogeneic cellular medicines," chair Jane Bell said.

She noted:

[Mesoblast has] an extensive clinical-stage pipeline of therapeutic assets validated by clinical data that address serious and life-threatening inflammatory illnesses. Our key areas of focus remain cardiovascular disease, chronic low back pain, and acute life-threatening inflammatory conditions including graft versus host disease (GvHD)…

2024 has been pivotal in our journey toward commercialising our therapies.

Bell said that the company's "positive interactions" with the United States Food and Drug Administration (FDA) enabled Mesoblast to resubmit the Biologics License Application for approval of Ryoncil (remestemcel-L).

The product is intended to help children with steroid-refractory acute GvH.

"As the current review for approval of Ryoncil progresses," Bell added, "our focus has turned to implementing the commercialisation strategies that will allow us to successfully launch Ryoncil, a much-needed treatment for desperately ill children, upon FDA approval."

In addition, the ASX biotech company is working towards filing for accelerated FDA approval of Revascor (rexlemestrocel-L) in end-stage heart failure patients.

As for the balance sheet, Bell noted:

Our balance sheet has been well-managed, including recently securing access to US$50 million to fund our planned commercial launch on approval of Ryoncil, while at the same time maintaining financial discipline through the implementation of cost reduction strategies to maximise our financial runway.

Looking at what might impact Mesoblast shares in the year ahead, Bell said, "As we plan for 2025 and beyond, I am very optimistic about Mesoblast's future."

She added, "The strength of our science, the dedication of our impressive team, and the support of our shareholders position us to achieve our goal of delivering transformative therapies to patients in need."

CEO Silviu Itescu reiterated that Mesoblast "expects to substantially advance its multiple product pipeline" toward FDA approvals over the next six to 12 months.

On the cost reduction front, which has helped support Mesoblast shares, Itescu highlighted the 26% year-on-year decline in the company's net operating cash spend for the September quarter.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »